Impact MRSA -PCR on Patient Management

MRSA Bacteremia Clinical Trial

Official title: Impact MRSA -PCR on Patient Management

Status Completed

Clinical Trial Summary

Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM).

With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse.

The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Bacteremia
• MRSA Bacteremia

• NCT number: NCT03096405
• Study type: Observational
• Source: Groupe Hospitalier Paris Saint Joseph
• Status: Completed
• Phase: N/A
• Start date: February 1, 2014
• Completion date: February 28, 2017